Reyvow
(Lasmiditan)ApprovedSmall molecule
Eli LillyLasmiditan is used to treat acute migraine headaches. It works by narrowing blood vessels around the brain and reducing substances in the body that can trigger headaches, nausea, sensitivity to light and sound, and other migraine symptoms.[2] Reyvow is currently approved and in use across 3 indications[4].[1]
Reyvow is one of 124 small molecule programs targeting Migraine Disorder. It is currently in Approved.
3
Indications
31
Total Trials
0
Active Trials
123
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
357 competitors in Migraine
#DrugCompanyPhaseTrials
1Reyvow
Eli LillyApproved
Aimovig
AmgenPreclinical
Emgality
Eli LillyPreclinical
Vyepti
LundbeckPreclinical
Bayer Aspirin
BayerPreclinical
Savella
AbbViePreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Cervidil
PfizerPreclinical
Pristiq
PPrism Pharmaceuticals
Preclinical
Bupivacaine Only
Pacira Pharmaceuticals, IncPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Migraine12 trials
Show 9 more trials
ART8 trials
Show 5 more trials
Driving2 trials
Impaired Renal Function1 trial
7 more indications
Hepatic Function1 trial
Abuse Potential1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jan 31, 2020
REYVOW
NDA NDA211280
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Reyvow drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Lasmiditan. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Reyvow. U.S. Food & Drug Administration.
- [7]